# D.C. Lung Cancer Conference 2023

## October 7, 2023 The Mayflower Hotel • Washington, D.C.



### **Course Director:**

#### Stephen V. Liu, MD

MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington, D.C.



Endorsed by:



## **#DCLUNG23**

### **Course Description**

This one-day conference will provide a comprehensive, multidisciplinary update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past year, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. This symposium will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on modern bronchoscopy, proton beam radiation, minimally invasive surgery and both neoadjuvant and adjuvant systemic therapy. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over use of emerging biomarkers to guide treatment of advanced NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review.

## Learning Objectives

- Identify the benefit of CT screening for lung cancer.
- Discuss the current application of liquid biopsy (or ctDNA analysis).
- Explain the approved adjuvant and neoadjuvant treatment options for resectable, driver negative non-small cell lung cancer (NSCLC).
- Discuss standard targeted agents in use for patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer.
- Describe the benefit of immunotherapy in the treatment of small cell lung cancer.
- Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
- Debate the use of targeted therapy for patients with resected Epidermal Growth Factor Receptor (EGFR) mutant non-small cell lung cancer.
- Explain the toxicity associated with targeted therapy given after immunotherapy in EGFR mutant non-small cell lung cancer.
- Discuss management of immune-mediated toxicities.
- Identify nursing strategies for early detection of immune-mediated toxicities.
- Recognize unique toxicities associated with targeted agents used in NSCLC.
- Describe current standard care for advanced mesothelioma.
- Discuss standard initial therapy for advanced small cell lung cancer (SCLC).
- List the currently approved targeted options for patients with MET exon 14 mutant lung cancer.
- Describe the role of the patient advocate in clinical research.
- Explain the significance and use of patient centered communications on the patient and family experience.
- Summarize strategies for navigating conversations with patients and families.
- Describe the approved use of tumor treating fields
- Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with lung cancer.
- Integrate a team-based approach in the care of patients with lung cancer.

### **Target Audience**

This conference is intended for medical oncologists, pathologists, pulmonologists, radiation oncologists, radiologists, surgeons, residents, fellows, physician assistants, nurses, pharmacists, medical students, allied health professionals, and other members of the healthcare team interested in the management of lung cancer.



### Accreditation

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses

Credentialing Center (ANCC) to provide continuing education for the healthcare team.



### **Credit Designation**

This activity was planned by and for the healthcare team, and learners will receive 7.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

**Physicians:** MedStar Health designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



American Board of Internal Medicine MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**MOC Participation Threshold:** Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 7.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: This activity is approved for 7.50 contact hours. This learning activity is knowledgebased. The Universal Activity Number for this program is UAN# JA4008151-0000-23-030-L05-P.

## **Course Director**



#### Stephen V. Liu, MD

Director, Thoracic Medical Oncology Head, Developmental Therapeutics MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Associate Professor, Medicine Georgetown University Medical Center Washington, D.C.

## Faculty

#### Nagla F. Abdel Karim, MD

Medical Oncologist Inova Health System Fairfax, VA Professor, Medicine University of Virginia Charlottesville, VA

#### Eric D. Anderson, MD

Director, Interventional Pulmonology MedStar Georgetown University Hospital Professor, Clinical Medicine Division of Pulmonary, Critical Care & Sleep Medicine Georgetown University Medical Center Washington, D.C.

#### Amin Benyounes, MD

Thoracic Medical Oncologist Inova Schar Cancer Institute Falls Church, VA

#### Hossein Borghaei, DO, MS

Chief, Thoracic Medical Oncology Professor, Hematology/Oncology The Gloria and Edmund M. Dunn Chair in Thoracic Oncology Fox Chase Cancer Center Philadelphia, PA

#### Ibiayi Dagogo-Jack, MD

Thoracic Medical Oncologist Massachusetts General Hospital Assistant Professor, Medicine Harvard Medical School Boston, MA

#### **Giuseppe Esposito, MD**

Chief, Nuclear Medicine and PET/CT MedStar Georgetown University Hospital Professor, Radiology Georgetown University Medical Center Washington, D.C.

#### Jill Feldman, MA

Lung Cancer Patient and Advocate Co-Founder EGFR Resisters Patient Group Deerfield, IL

#### Narjust Florez, MD

Associate Director, Cancer Care Equity Program Thoracic Medical Oncologist Dana-Farber Brigham Cancer Center Assistant Professor, Medicine Harvard Medical School Boston, MA

#### Patrick Forde, M.B.B.Ch.

Director, Thoracic Oncology Clinical Research Program Co-Director, Division of Upper Aerodigestive Malignancies Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Associate Professor, Oncology Johns Hopkins University School of Medicine Baltimore, MD

#### Marina Chiara Garassino, MBBS

Director, Thoracic Oncology Program Professor, Medicine The University of Chicago Medicine Chicago, IL

#### Ryan D. Gentzler, MD

Medical Oncologist, Thoracic Oncology Associate Professor, Medicine University of Virginia Comprehensive Cancer Center Charlottesville, VA

## Faculty

#### Balazs Halmos, MD

Associate Director, Clinical Science Montefiore Einstein Cancer Center Professor, Medicine Albert Einstein College of Medicine Bronx, NY

#### Faysal Haroun, MD

Fellowship Program Director Assistant Professor, Medicine Division of Hematology & Oncology The George Washington University School of Medicine and Health Sciences Washington, D.C.

#### Raffit Hassan, MD

Chief, Thoracic and GI Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda, MD

#### Chul Kim, MD, MPH

Thoracic Medical Oncologist MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Associate Professor, Medicine Georgetown University Medical Center Washington, D.C.

#### Ticiana Leal, MD

Director, Thoracic Medical Oncology Program Department of Hematology and Medical Oncology Associate Professor, Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA

#### Natasha B. Leighl, MD, MMSc

Lung Site Lead, Medical Oncology Princess Margaret Cancer Centre Professor, Medicine University of Toronto Adjunct Professor, Medicine Dalla Lana School of Public Health Toronto, Canada

#### Benjamin P. Levy, MD

Thoracic Medical Oncologist Clinical Director, Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor, Oncology Johns Hopkins University School of Medicine Washington, D.C.

#### Jessica J. Lin, MD

Thoracic Medical Oncologist Attending Physician, Center for Thoracic Cancers Attending Physician, Henri and Belinda Termeer Center for Targeted Therapies Massachusetts General Hospital Assistant Professor, Medicine Harvard Medical School Boston, MA

#### Jennifer A. Marks, MD

Hematology & Oncology Fellow MedStar Georgetown University Hospital Washington, D.C.

#### Michael E. Menefee, MD

Assistant Professor, Medicine George Washington University School of Medicine Washington, D.C. VA Medical Center Washington, D.C.

#### Drew Moghanaki, MD, MPH

Professor and Chief, Thoracic Oncology Service Stanley lezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research Department of Radiation Oncology UCLA Health Jonsson Comprehensive Cancer Center Los Angeles, CA

#### Nitika Paudel, MD, PhD

Radiation Oncologist, Radiation Medicine MedStar Georgetown University Hospital Assistant Professor, Radiation Medicine Georgetown University Medical Center Washington, D.C.

#### Zofia Piotrowska, MD, MHS

Thoracic Medical Oncologist Massachusetts General Hospital Assistant Professor, Medicine Harvard Medical School Boston, MA

#### Joshua E. Reuss, MD

Thoracic Medical Oncologist MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Assistant Professor, Medicine Georgetown University Medical Center Washington, D.C.

## Faculty

#### Katherine A. Scilla, MD

Thoracic Medical Oncologist University of Maryland Greenebaum Comprehensive Cancer Center Assistant Professor, Medicine University of Maryland School of Medicine Baltimore, MD

#### Susan C. Scott, MD

Thoracic Medical Oncologist Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Sibley Memorial Hospital Assistant Professor, Oncology Johns Hopkins University School of Medicine Baltimore, MD

#### Elaine Shum, MD

Thoracic Medical Oncologist NYU Perlmutter Cancer Center Assistant Professor, Medicine NYU Grossman School of Medicine New York, NY

#### Jonathan Spicer, MD

Director, Thoracic Oncology Biobank Medical Director, McGill Thoracic Oncology Network Program Director, Advanced Thoracic and Upper GI Surgical Oncology Fellowship Associate Professor, Surgery McGill University Montreal, Canada

#### Alexander I. Spira, MD, PhD

Director, Thoracic and Phase I Program Co-Director, VCS Research Institute Clinical Assistant Professor, Oncology Virginia Cancer Specialists Fairfax, VA

#### Brendon M. Stiles, MD

Associate Director, Surgical Services Montefiore-Einstein Cancer Center Professor and Chief, Thoracic Surgery and Surgical Oncology Albert Einstein College of Medicine Montefiore Medical Center New York, NY

#### Jillian E. Thompson, ANP-BC, AOCNP

Nurse Practitioner, Hematology and Oncology MedStar Georgetown University Hospital Washington, D.C.

#### Irina G. Veytsman, MD

Section Director, Hematology and Oncology Medical Oncologist MedStar Washington Hospital Center MedStar Georgetown Cancer Institute Washington, D.C.

#### Randi M. Williams, PhD, MPH

Assistant Professor, Oncology Georgetown University Medical Center Washington, D.C.



## Agenda

7:30 a.m.	Registration and Continental Breakfast	SESSION Moderator: A	
8:00 a.m.	Welcome and Introduction Stephen V. Liu, MD	9:40 a.m.	<b>Treatr</b> Stage Michae
PREVEN	I <b>  DIAGNOSIS &amp;</b> FION Chul Kim, MD, MPH	9:50 a.m.	<b>When</b> Appro Nitika
8:05 a.m.	The Art of Oncology: Learning from Patients' Lived Experiences Jill Feldman, MA	10:00 a.m.	Can V to Res Jonath
8:15 a.m.	Lung Cancer Screening in the Smoking and Non-Smoking Population	10:10 a.m.	<b>Checl</b> Patrick
8:25 a.m.	Elaine Shum, MD Integrating Smoking Cessation	10:20 a.m.	Adjuv Immu
0.20 0.111	in the Lung Cancer Control Setting Randi M. Williams, PhD, MPH	10:30 a.m.	Marina Targe NSCL
8:35 a.m.	<b>State of the Art Bronchoscopic</b> <b>Techniques</b> Eric D. Anderson, MD	10:40 a.m.	Narjus <b>Sub-L</b> Marc M
8:45 a.m.	Best Practice: Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC) Ryan D. Gentzler, MD	10:50 a.m.	<b>Sessio</b> Moder Panelis M. Gar
8:55 a.m.	The Current Utility of Liquid Biopsy		M. Me N. Pau
0.05	Natasha B. Leighl, MD, MMSc	11:00 a.m.	<b>Deba</b> Ann E.
9:05 a.m.	DOTATATE: Diagnosis and Treatment Giuseppe Esposito, MD	11:05 a.m.	<b>Deba</b> Radio Drew I
9:15 a.m.	Session I Panel Discussion Moderator: Chul Kim, MD, MPH Panelists: E. Anderson, G. Esposito, J. Feldman, R. Gentzler, N. Leighl, C. Lovely, E. Shum, R. Williams	11:15 a.m.	<b>Deba</b> for Sta Brende
9:25 a.m.	Coffee Break and Visit the Exhibits	11:25 a.m.	Lunch

RLY-STAGE NSCLC walek, DO, MS

9:40 a.m.	<b>Treatment of Unresectable Stage III NSCLC</b> Michael E. Menefee, MD
9:50 a.m.	When is Proton Radiation Appropriate? Nitika Paudel, MD, PhD
10:00 a.m.	Can We Convert Unresectable to Resectable? Jonathan Spicer, MD
10:10 a.m.	<b>CheckMate 816: A History</b> Patrick Forde, M.B.B.Ch.
10:20 a.m.	<b>Adjuvant vs. Neoadjuvant Immunotherapy</b> Marina Chiara Garassino, MBBS
10:30 a.m.	<b>Targeted Therapy in Early-Stage NSCLC</b> Narjust Florez, MD
10:40 a.m.	Sub-Lobar Resection for NSCLC Marc Margolis, MD
10:50 a.m.	Session II Panel Discussion
	Moderator: Joshua E. Reuss, MD Panelists: N. Florez, P. Forde, M. Garassino, M. Margolis, M. Menefee, D. Moghanski, N. Paudel, J. Spicer, B. Stiles
11:00 a.m.	Panelists: N. Florez, P. Forde, M. Garassino, M. Margolis, M. Menefee, D. Moghanski,
11:00 a.m. 11:05 a.m.	Panelists: N. Florez, P. Forde, M. Garassino, M. Margolis, M. Menefee, D. Moghanski, N. Paudel, J. Spicer, B. Stiles <b>Debate Introduction</b>
	Panelists: N. Florez, P. Forde, M. Garassino, M. Margolis, M. Menefee, D. Moghanski, N. Paudel, J. Spicer, B. Stiles <b>Debate Introduction</b> Ann E. Hwalek, DO, MS <b>Debate: Stereotactic Body</b> <b>Radiotherapy (SBRT) for Stage I</b>

## Agenda

11:55 a.m.	Lunch Symposium: Personalizing Treatment for Adult Patients with Advanced NSCLC	2:25
	Sponsored by Regeneron This symposium is not certified for continuing education credit.	2:35
12:40 p.m.	Dessert and Visit the Exhibits	SES FOF
SESSION I		Mode
	ANCED LUNG CANCER hul Kim, MD, MPH	2:45
1:10 p.m.	<b>Updates in Small Cell Lung Cancer (SCLC): Is a Personalized Approach Possible?</b> Nagla F. Abdel Karim, MD	2:55 J
1:20 p.m.	<b>Mesothelioma: State of the Art</b> Raffit Hassan, MD	3:05 <sub> </sub>
1:30 p.m.	Competing Strategies for NSCLS PD-L1 ≥ 50%: Which One Should We Pick? Benjamin P. Levy, MD	3:15 p
1:40 p.m.	Immunotherapy Combinations for PD-L1 Low and Negative NSCLC Hossein Borghaei, DO, MS	3:25
1:50 p.m.	Immunotherapy Toxicity Jillian E. Thompson, ANP-BC, AOCNP	3:35 j
2:00 p.m.	<b>Session III Panel Discussion</b> Moderator: Chul Kim, MD, MPH Panelists: H. Borghaei, R. Hassan, N. Karim, B. Levy, J. Reuss, S. Scott, J. Thompson	3:45 j
2:10 p.m.	Debate Introduction Chul Kim, MD, MPH	2.55
2:15 p.m.	Debate: STK11 / KEAP1 Influence Use of Immunotherapy Susan C. Scott, MD	3:55 j

<b>K11 / KEAP1 Do Not</b> <b>Jse of Immunotherapy</b> euss. MD

2:35 p.m. Afternoon Break and Visit the Exhibits

#### SESSION IV | TARGETED THERAPY FOR ADVANCED NSCLC #1

Moderator: Joshua E. Reuss, MD

Management of Sensitizing **Epidermal Growth Factor** Receptor (EGFR) Mutant NSCLC Zofia Piotrowska, MD, MHS Progress for EGFR Exon 20 Insertion NSCLC Chul Kim, MD, MPH **Best Practice for Anaplastic** Lymphoma Kinase (ALK) + NSCLC Jessica J. Lin, MD Targeting ROS1, Neurotrophic **Tropomyosin-receptor Kinase** (NTRK), and NRG1 Fusions in NSCLC Faysal Haroun, MD **BRAF: V600E and Beyond** Ibiayi Dagogo-Jack, MD Updates on HER2 and RET in NSCLC Amin Benyounes, MD Session IV Panel Discussion Moderator: Joshua E. Reuss, MD Panelists: A. Benyounes, I. Dagogo Jack, F. Haroun, C. Kim, J. Lin, Z. Piotrowska Afternoon Break and Visit the Exhibits

## Agenda

#### SESSION V | TARGETED THERAPY FOR ADVANCED NSCLC #2

Moderator: Jennifer Marks, MD

- 4:05 p.m. Don't Skip MET! Balazs Halmos, MD
- 4:15 p.m. Antibody Drug Conjugates for Lung Cancer Katherine A. Scilla, MD
- 4:25 p.m. KRAS G12C in NSCLC Irina G. Veytsman, MD
- 4:35 p.m. KRAS: Beyond G12C Alexander I. Spira, MD, PhD

4:45 p.m. Tumor Treating Fields and Thoracic Tumors Ticiana Leal, MD

- 4:55 p.m. Session V Panel Discussion Moderator: Jennifer Marks, MD Panelists: B. Halmos, T. Leal K. Scilla, A. Spira, I. Veytsman
- 5:00 p.m.

#### Closing Remarks and Conference Adjourn Stephen V. Liu, MD



## **Venue Information**

### The Mayflower Hotel

1127 Connecticut Avenue NW Washington, DC 20036

Phone: (202) 347-3000



## **Registration Information**

<b>Registration Fees</b>	Early Bird Rate now through August 7	<b>Early Bird Rate</b> August 7 to October 7
Physician	\$175	\$200
IASLC Member	\$140	\$140
Resident/Fellow	\$0	\$0
Physician Assistant	\$100	\$125
Nurse Practitioner	\$100	\$125
Nurse	\$100	\$125
Allied Health Professional	\$100	\$125

### **Online Registration Preferred**

Please visit **MedStarHealth.org/DCLung23** for updated program and registration information. We are unable to accept registrations or cancellations by telephone.

All registrations will be confirmed by email only. If you have questions or do not receive a confirmation within 1-2 business days, please contact us at MedStarCPE@MedStar.net or (833) 731-1273.

### **Cancellation Policy**

Cancellations made in writing by August 25, 2023 will be subject to a 50% penalty. No refunds will be given after August 25. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

### **Special Assistance**

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact (833) 731-1273 to notify us of your needs.

For grant information please contact Ada Guo at ada.guo@medstar.net For exhibit information please contact Elizabeth Romano at elizabeth.s.romano@medstar.net